Gentamicin-induced ototoxicity and nephrotoxicity vary with circadian time of treatment and entail separate mechanisms

Abstract

The aminoglycoside antibiotic gentamicin can cause both ototoxicity and nephrotoxicity, the severity of which varies with circadian time of daily treatment. However, it is not yet resolved if such drug-induced adverse effects are independent or dependent phenomena. Two groups of 9 female Sprague-Dawley rats (200-250 g), each housed separately, entrained to a 12h light (06:00 to 18:00h)-12h dark cycle, received a daily subcutaneous injection of 100 mg/kg gentamicin. One group was treated at the beginning of the activity span, 2 HALO (Hours After Lights On), and the other at the beginning of the rest span, 14 HALO. Global toxicity was gauged both by body weight loss relative to the pre-treatment baseline and number of deaths. Ototoxicity, i.e., hearing loss, was assessed by changes in Auditory Brainstem Responses (ABR) for pure tone stimuli of 8, 16, 24, and 32 kHz before and after 2 and 4 weeks of gentamicin treatment. Renal toxicity was evaluated by changes in urinary N-acetyl-β-glucosaminidase (NAG)/creatinine (CR) concentration ratio before and after each week of treatment. In a complementary substudy of separate but comparable 2 and 14 HALO groups of rats, blood samples were obtained before and 30, 60, 120, and 240-mins post-subcutaneous injection of 100 mg/kg gentamicin. Number of animal deaths was greater in the 2 (4 deaths) than 14 HALO (1 death) group, mirroring more severe initial (1st 2 weeks of treatment) body weight losses from baseline, being more than 2-fold greater in animals of the 2 than 14 HALO group. Ototoxicity progressively worsened during treatment; although, the extent of hearing loss varied according to circadian time of treatment across all frequencies (p<0.05), particularly the 24 and 32 kHz ones (both p<0.005), both at the 2 and 4 week assessments. At 32 kHz after 4 weeks of gentamicin dosing, the 2 HALO group showed an average 42 dB hearing loss, while the 14 HALO group exhibited only an average 10 dB loss. ABR response latencies were longer for the 2 than 14 HALO rats. The time course of nephrotoxicity differed from that of ototoxicity. The mean urinary NAG/CR ratio peaked after the 1st week of treatment, averaging 13.64-fold greater than baseline for the 2 HALO-treated animals compared to 7.38-fold greater than baseline for the 14 HALO-treated ones. Ratio values declined thereafter; although even after the 2nd week of dosing, they remained greater in the 2 than 14 HALO group (averaging 8.15-fold greater and 2.23-fold greater than baseline, respectively). Pharmacokinetic analysis of the blood gentamicin values revealed slower clearance, on average by ∼25% (p<0.001), in the rats of the 14 than 2 HALO group (x̄ ± S.E.: 3.22 ± 0.49 and 4.53 ± 0.63 mL/min/kg, respectively). The study findings indicate robust difference of the time course in rats of both treatment groups of gentamicin-induced ototoxicity and nephrotoxicity, supporting the hypothesis these organ toxicities are independent of one another, and further suggest the observed treatment-time differences in gentamicin adverse effec...

Clinical chronobiology: a timely consideration in critical care medicine

“…Chronotherapeutic strategies have proved beneficial in cancer treatment [ 98 ] where circadian-timed chemotherapy may improve outcomes. Optimising the timing of drugs with a narrow therapeutic index and significant circadian fluctuation, such as antibiotics, steroids and anticoagulants, could lead to significant clinical benefit from improvements in efficacy and minimisation of toxicity [ 97 , 99 ]. Benzodiazepines phase-shift the clock according to the time of day at which they are administered [ 100 ], and thus the circadian disruption effect could be minimised by administering the drug at the correct time of day relative to the patient’s circadian phase.…”

Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics

“…In accordance, higher nephrotoxicity and ototoxicity were demonstrated when it was dosed at the rest phase (ZT 2) in female rats, although clearance values were slightly higher at ZT 2 than ZT 14 (4.53 vs. 3.22 ml·min −1 ·kg −1 ; Blunston, Yonovitz, Woodahl, & Smolensky, 2015). Similarly, Oda et al evaluated the nephrotoxicity of cisplatin in mice and reported it as less toxic when clearance is higher, that is, active phase.…”

Protective Effect of Ginkgo Biloba Extract on Gentamicin-Induced Structural Changes of Calcite-Gelatin Composite

“…Aminoglycoside antibiotics have been used for the treatment of gram-negative bacterial infection. However, these drugs have significant risks of nephrotoxicity and ototoxicity [21] . In the inner ear, systemic aminoglycosides cross the blood-labyrinth barrier (BLB) and can damage cochlear hair cells through several mechanisms such as apoptosis or release of reactive oxygen species (ROS), leading to permanent sensorineural hearing loss [22,23] .…”